anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
After having signed informed consent (Day 0), the patients will be screened for enrollment. About 1500 eligible patients will be enrolled in this study. The basic information of eligible patients including demographic characteristics, history of present illness, past history, Rose questionnaire, vital sign, medication information, SAQ and other optional examination data will be collected at Day 0. At Day 0, the patients will join the study Wechat Mini Program developed for online follow up and patient education by scan the QR code provided by investigators. After enrollment, the following information will be collected by ePRO with WeChat Mini Program or telephone follow up of month 3, 6 and 9: vital sign, medication information, SAQ, AE. The follow up of month 12 will be conducted on site which will collect SAQ, AE and other optional examination data.
Fusion inhibitor peptides are provided comprising a sequence derived from an HR2 domain. In preferred embodiments, the peptides are capable of oligomerization. Also provided are nucleic acids encoding the peptides, vectors comprising the nucleic acids and host cells transformed with the vectors. The peptides may be used as medicaments. Also provided are methods for expressing a protein comprising one or more transmembrane domain(s) in an expression system. The methods comprise fusing a sequence encoding an 18-mer peptide, or a functional equivalent thereof, to a gene encoding the protein and expressing the resultant gene-fusion product in an expression system.
PURPOSE: A silk peptide composition is provided to offer high molecular weight of silk peptide composition which is merely absorbed into human body and has complex function of improving hypercholesterolemia and hyperlipidemia by using silk protein. CONSTITUTION: A functional food composition is produced by decomposing silk protein and includes 10000-100000 weight-average molecular weight of silk peptides as an active ingredient. The improvement on blood lipid related diseases is improvement of total cholesterol in blood, improvement of LDL(low density lipoprotein) cholesterol in blood or improvement of triglyceride in blood. The silk protein is silk fibroin. The silk protein decomposition is performed by a decomposition method selected from a group consisting of decomposition in calcium salt solution, acidic hydrolysis, decomposition by a mixture solution of calcium salt and ethanol and a combination thereof. The calcium salt is calcium chloride. The calcium salt removal is selected from a method consisting of dialysis, ultrafiltration, gel chromatography, electric desalting and a combination thereof.
After the easing of COVID-19 restrictions, peaks of common infectious diseases surpassed pre-pandemic levels, raising questions about causes and ways to monitor these changes. A proposed measure, the Pathogen Population Density (PPD) score, could help track these shifts. PPD refers to the concentration of infectious agents within a population at a given time and location, serving as a potential indicator of infection levels in susceptible individuals at the population level. It is likely that PPD remains relatively stable within a specific community, as an equilibrium forms between infections and susceptibility. During the pandemic, nonpharmaceutical interventions (NPIs) led to a reduction in infectious diseases, possibly lowering population immunity and decreasing the PPD score. Once NPIs were lifted, the PPD score likely increased sharply due to a larger pool of susceptible individuals, causing more primary infections and stronger recurrent infections, faster transmission, and more severe pathogenic outcomes at the individual level. Monitoring the PPD score over time could help predict when infection peaks will occur. PPD is influenced by factors such as public health strategies, vaccination programs, and the behavior of high-risk individuals. As a quantitative measure, PPD has the potential to serve as a valuable predictive and monitoring tool, helping public health officials anticipate and track changes in infectious disease dynamics. It could be an effective tool for managing future outbreaks or pandemics and serve as a communication tool between scientists and the public to understand the emergence of new disease peaks.
Doxorubicin (DOX) is a chemotherapy drug used to treat various types of cancer, but it is associated with significant side effects such as skeletal muscle atrophy. Exercise has been found to prevent skeletal muscle atrophy through the modulation of mitochondrial pathways. Mitochondrial transplantation (MT) may mitigate toxicity, neurological disorders, kidney and liver injury, and skeletal muscle atrophy. The objective of this study was to evaluate the effects of MT, exercise, and MT with exercise on DOX-induced skeletal muscle atrophy. Male Sprague Dawley rats were randomly assigned to the following groups: control, DOX, MT with DOX, exercise with DOX, and exercise with MT and DOX. A 10-day treadmill running exercise and MT (6.5 µg/100 µL) to tibialis anterior (TA) muscle were administered prior to a single injection of DOX (20 mg/kg). Our data showed that exercise and MT with exercise led to an increase in cross-sectional area of the TA muscle. Exercise, MT and MT with exercise reduced inflammation and maintained mitochondrial enzyme activity. Additionally, exercise and MT have been shown to regulate mitochondrial fusion/fission. Our findings revealed that exercise and MT with exercise prevented oxidative damage. Furthermore, MT and MT with exercise decreased apoptosis and MT with exercise triggered mitochondrial biogenesis. These findings demonstrate the importance of exercise in the prevention of skeletal muscle atrophy and emphasize the significant benefits of MT with exercise. To the best of our knowledge, this is the first study to demonstrate the therapeutic effects of MT with exercise in DOX-induced skeletal muscle atrophy.
A method and system for personalized non-invasive assessment of renal artery stenosis for a patient is disclosed. Medical image data of a patient is received. Patient-specific renal arterial geometry of the patient is extracted from the medical image data. Features are extracted from the patient-specific renal arterial geometry of the patient. A hemodynamic index is computed for one or more locations of interest in the patient-specific renal arterial geometry based on the extracted features using a trained machine-learning based surrogate model. The machine-learning based surrogate model is trained based on features extracted from synthetically generated renal arterial geometries.
BACKGROUND: Abdominal pain and vomiting are frequent complaints for pediatric patients presenting to the Emergency Department (ED). When a diagnosis such as chronic abdominal pain, cyclic vomiting, or abdominal migraine has previously been made, it can lead to diagnostic momentum and confirmation bias on behalf of the treating physician. Dietl's crisis is a commonly missed diagnosis in the pediatric population that presents with intermittent episodes of pain and vomiting. It can be readily diagnosed at the bedside by the emergency physician (EP) through the employment of point of care ultrasound (POCUS).
CASE SERIES: We present two cases of pediatric patients with episodic abdominal pain and vomiting who were previously diagnosed with cyclic vomiting syndrome. In both cases, pediatric gastroenterology evaluations had occurred with negative diagnostic testing having been performed. Both patients also presented to their primary pediatrician and the ED multiple times with each encounter resulting in treatment of symptoms and discharge. Each patient eventually presented to the ED when an EP was present who performed a renal POCUS. In each patient, the POCUS revealed severe unilateral hydronephrosis. Subsequent workup confirmed the diagnosis of Dietl's crisis as the etiology of symptoms. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: In pediatric patients, EPs should be wary of the diagnosis of cyclic vomiting syndrome until ureteral obstruction has been ruled out. A bedside POCUS can rapidly establish this diagnosis and potentially preclude recurrent health care visits, unnecessary diagnostic testing, and permanent loss of renal function.
First neck and trunk exercise involved lifting the head in a modified bridge exercise position so that lower abdominal muscles contracted when the neck was bent, thereby activating the neck flexor muscle and the lower abdominal muscles simultaneously. Second exercise involved pushing the neck backward in supine position to activate the erector muscles of the neck and the upper thoracic vertebrae through the extension of the muscles of the back of the neck. Third exercise activated the deep abdominal muscles in bridge exercise positions so that the participants would experience the posterior inclined movement of the pelvis. Keep each posture for 10 seconds at a time and repeat 10 times with a rest interval of 3 seconds per each.
The invention relates to the technical field of high-molecular prodrugs, in particular to N-carboxyanhydride, and a preparation method and application thereof. The invention provides N-carboxyanhydride, which has a structure shown in a formula I; the N-carboxyanhydride provided by the invention contains SO 2 Donors, capable of producing releasable SO by ring-opening polymerisation 2 The polyamino acid material of (1). The polyamino acid material can be self-assembled into nanoparticles in water. Cell experiments show that the blank nano-particlesCan be endocytosed into tumor cells, and then rapidly releases SO under the action of high-concentration glutathione 2 The concentration of glutathione is reduced while the level of active oxygen is increased, and finally the oxidative damage of cancer cells is caused, thereby killing the tumor cells. In addition, the negative control material did not have this anticancer effect. The polyamino acid material has a treatment effect, and can play an anti-tumor biological activity without the participation of chemotherapeutic drugs.
Participants will receive pentostatin on days -21, -17, -13, and -9 and oral cyclophosphamide from days -21 to -8. Alemtuzumab to be infused on days -7 to -3, followed by 400 cGy TBI on day -1. Donor-derived peripheral blood stem cells will be given on Day 0 then cyclophosphamide will be given at 50 mg/kg on day +3. Sirolimus loading dose of 5mg PO q4h x three doses at one day after the completion of cyclophosphamide (on day +4) and continued the following day at 5mg PO q24h to maintain trough levels between 5-15 ng/ml.
PURPOSE: There is a need for robust earlier biomarkers of atrophic age-related macular degeneration that could act as surrogate endpoints for geographic atrophy (GA) in early interventional trials. This study sought to examine the risk of progression of complete retinal pigment epithelium and outer retinal atrophy (cRORA) to the traditional atrophic endpoint of GA on color fundus photography. This study also compared the risk of progression for cRORA to that associated with the specific optical coherence tomography features that define nascent GA (nGA), a strong predictor of GA development.
METHODS: One hundred forty participants with bilateral large drusen at baseline underwent optical coherence tomography imaging and color fundus photography at 6-month intervals for up to 36 months. Optical coherence tomography volume scans were graded for the presence of cRORA and nGA, and color fundus photographs were graded for the presence of GA. The association and rate of progression to GA for cRORA and nGA were examined.
RESULTS: Both cRORA and nGA were significantly associated with GA development (adjusted hazard ratio, 65.7 and 76.8 respectively; both P < 0.001). The probability of progression of cRORA to GA over 24 months (26%) was significantly lower than the probability of progression of nGA (38%; P = 0.039).
CONCLUSION: This study confirmed that cRORA was a significant risk factor for developing GA, although its rate of progression was slightly lower compared with nGA. While requiring replication in future studies, these findings suggest that the specific features of photoreceptor degeneration used to define nGA appear important when assessing the risk of progression.
The invention discloses a gene editing system for constructing a swine nuclear transplantation donor cell of a DOK7 gene mutated myasthenia disease model and application thereof. The present invention provides SEQ ID NO:16, and the sequence of DOK7-gRNA2 shown in SEQ ID NO:17, and the application of the DOK7-gRNA4 and the NCN protein in the preparation of the kit. The invention also provides a method for preparing recombinant cells, which comprises the following steps: and co-transfecting the DOK7-gRNA2, the DOK7-gRNA4 and the NCN protein into the pig cells to obtain recombinant cells. The recombinant cell is a recombinant cell with a mutant DOK7 gene. The use of any one of the above kits is: preparing a recombinant cell; preparing a muscle weakness model pig; preparing a muscle weakness cell model or a muscle weakness tissue model or a muscle weakness organ model. The invention has great application value for researching and developing the medicine for treating the myasthenia and disclosing the pathogenesis of the myasthenia.
Dietary Supplement: BK003 The product is a combination of chitin-glucan and micronutrients. The dose of chitin-glucan is 3 g/day. The product is provided as sachets containing powder to be dissolved in a glass of water (about 250 ml) and taken orally.
During Treatment Period 1, on study Day 1, participants received a single dose of sildenafil followed by wash out on Day 2. In Period 2 (study Days 3-7), participants received LCZ696 once daily. In Period 3, on study Day 8, participants received LCZ696 , co-administered at the same time with a single dose of sildenafil.
The invention discloses a Chinese herbal medicine preparation for treating hyperplasia of mammary glands. In order to overcome the defects in the background art, the invention provides a Chinese herbal medicine preparation for treating hyperplasia of mammary glands, which has the advantages of low price, obvious curative effect, short treatment period and no relapse and is convenient to use. The Chinese herbal medicine preparation for treating hyperplasia of mammary glands is prepared from the following Chinese herbal medicines: trichosanthes kirilowii Maxim, Gueldenstaedtia verna, antler, rhizoma pleionis, polygala japonica, geranium wilfordii, rhizoma bolbostemmae, Vincetoxicum amplexicaule, madder, pangolin and the like. The preparation method of the Chinese herbal medicine preparation for treating hyperplasia of mammary glands comprises the following steps: removing non-medicinal parts, washing, cleaning, drying, weighing according to the proportion, merging, pulverizing, passing through an 80 mesh screen, sterilizing, drying and packaging. The Chinese herbal medicine preparation for treating hyperplasia of mammary glands is taken with warm water three times a day, 10g a time. The treatment course is 15 days. The clinical data statistical analysis on 300 patients with hyperplasia of mammary glands indicates that the shortest time for treating hyperplasia of mammary glands is 1 week, the longest time is 3 weeks, and the effective rate is 100%.
PURPOSE:To provide an antilipemic agent composed mainly of a strongly basic anion exchange resin having a polymeric quaternary salt and an imidazolium salt as functional groups. CONSTITUTION:The objective antilipemic agent contains, as a main component, a strongly basic anion exchange resin which is a copolymer of (A) the polymeric quaternary salt of formula I (R1 is H, 1-17C alkyl, etc.; R2 and R3 are H or 1- 3C alkyl; R4 is H or methyl; Y<-> is halogen ion, hydroxyl ion, etc.; n is integer of >=1; Ar is group of formula II, formula III, etc.; X is halogen, group of formula IVor group of formula V) and (B) a polyfunctional epoxy compound having two or more oxirane rings, and containing an imidazolium salt as a functional group having a counter ion selected from halogen ion, hydroxyl ion, etc. The above ion exchange resin is free from ill odor, and has high adsorption activity to bile acid. The particle size of the agent is finer than 50 mesh, preferably 50- 325 mesh.
Participants in this arm will undergo a 30-minute session of floor sitting on a cushioned mat. They will engage in the same desk activities as the chair sitting arm to maintain consistency across conditions.
PURPOSE OF REVIEW: This review aims to provide an overview of recent research findings regarding immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, focusing on clinical and immunological novelties, as well as emerging treatment strategies, based on the published literature of the last few years.
RECENT FINDINGS: While it is well known that IPEX can present with a wide range of atypical clinical manifestations, new and unique phenotypes continue to emerge, making it essential to maintain a high level of clinical suspicion both at the time of diagnosis and during follow-up. This unpredictability in clinical presentation is further compounded by the lack of a clear genotype-phenotype correlation. A valuable tool for monitoring comes from recent discoveries regarding the epigenetic signature of Tregs, which, by correlating with disease severity, could prove to be a useful biomarker for diagnosis and ongoing management. The use of biological agents is emerging as an alternative to traditional immunosuppression. Additionally, ongoing studies are exploring the feasibility of gene therapy through the introduction of the wild-type FOXP3 into peripheral CD4 + T cells.
SUMMARY: Further research is needed to fully understand the variable clinical presentations of IPEX and optimize tailored therapies, ensuring better management and outcomes for affected individuals.
BACKGROUND: Lumbar disc herniation (LDH) is the main clinical cause of low back pain. The pathogenesis of lumbar disc herniation is still uncertain, while it is often accompanied by disc rupture. In order to explore relationship between loading rate and failure mechanics that may lead to lumbar disc herniation, the failure mechanical properties of the intervertebral disc under high rates of loading were analyzed.
METHOD: Bend the lumbar motion segment of a healthy sheep by 5° and compress it to the ultimate strength point at a strain rate of 0.008/s, making a damaged sample. Within the normal strain range, the sample is subjected to quasi-static loading and high loading rate at different strain rates.
RESULTS: For healthy samples, the stress-strain curve appears collapsed only at high rates of compression; for damaged samples, the stress-strain curves collapse both at quasi-static and high-rate compression. For damaged samples, the strengthening stage becomes significantly shorter as the strain rate increases, indicating that its ability to prevent the destruction is significantly reduced. For damaged intervertebral disc, when subjected to quasi-static or high rates loading until failure, the phenomenon of nucleus pulposus (NP) prolapse occurs, indicating the occurrence of herniation. When subjected to quasi-static loading, the AF moves away from the NP, and inner AF has the greatest displacement; when subjected to high rates loading, the AF moves closer to the NP, and outer AF has the greatest displacement. The Zhu-Wang-Tang (ZWT) nonlinear viscoelastic constitutive model was used to describe the mechanical behavior of the intervertebral disc, and the fitting results were in good agreement with the experimental curve.
CONCLUSION: Experimental results show that, both damage and strain rate have a significant effect on the mechanical behavior of the disc fracture. The research work in this article has important theoretical guiding significance for preventing LDH in daily life.
OBJECTIVE: Misophonia is a psychiatric condition characterized by strong emotional and/or behavioral responses to auditory stimuli, leading to distress and functional impairment. Despite previous attempts to define and categorize this condition, misophonia is not currently included in the Diagnostic and Statistical Manual of Mental Disorders or International Classification of Diseases. The lack of formal diagnostic consensus presents challenges for research aimed at assessing and treating this clinical presentation.
METHODS: The current study presents clinical characteristics of youth (N = 47) with misophonia in the largest treatment-seeking sample to date. We examined demographic characteristics of the sample, frequency of comorbid disorders, frequency of specific misophonia symptoms (i.e., triggers, emotional and behavioral responses, and impairments), and caregiver-child symptom agreement. Misophonia symptoms were evaluated using a multimodal assessment including clinician, youth, and caregiver reports on empirically established misophonia measures, and concordance among measures was assessed.
RESULTS: Youth seeking treatment for misophonia presented with marked misophonia symptoms and an array of comorbid conditions. Youth and caregivers identified various triggers of misophonia symptoms (e.g., chewing sounds, breathing sounds), as well as a wide range of emotional (e.g., anger, annoyance, disgust) and behavioral (e.g., aggression, avoidance) responses to triggers. Youth and caregivers exhibited high agreement on misophonia triggers but lower agreement on symptom severity and associated impairment. Compared to younger children (aged 8-13), older children (aged 14+) appeared to report symptom severity and associated impairment more reliably.
CONCLUSION: Misophonia is a heterogenous and impairing clinical condition that warrants future investigation and evidence-based treatment development.
Compositions and dosage forms for administering abusable substances are disclosed which have a reduced potential for abuse without diminishing the therapeutic or beneficial effects of the abusable substance. Topical compositions for application to the skin or mucosa contain the abusable substance in a form which is permeable to the skin or mucosa to which it is to be applied and an antagonist for the abusable substance is present in the composition in an abuse negating amount and in a form that is impermeable to the skin or mucosa to which the composition is to be applied. Controlled release dosage forms which release the abusable substance from a drug reservoir composition confined behind a release rate controlling barrier have the abusable substance and its antagonist in the drug reservoir. The abusable substance is present in a form that is releasable from the dosage form and the antagonist is present in an abuse negating amount in a form that is not releasable from the dosage form. Thus the compositions and dosage forms of this invention permit the therapeutic use, at substantially full potency, of an abusable substance when use as prescribed but reduce the abuse potential of the compositions and dosage forms by other routes of administration. Preferred embodiments of the invention utilize fentanyl as the abusable substance and naltrexone as the antagonist in a transdermal dosage form.
[US5236714A]